Novartis

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases

Retrieved on: 
Wednesday, February 28, 2024
Doctor of Philosophy, Decorin, Drug development, Sale, Iris (anatomy), Transferrin, Ciliary muscle, Geographic atrophy, Ranibizumab, Iron, Retinitis pigmentosa, Retina, CNV, Paratriathlon, Eye, Brolucizumab, VEGF, Therapy, AMD, Independent, DNA, Retinal pigment epithelium, KIP, Doctor of Pharmacy, Safety, Novartis, Oxidative stress, CSO, Conditional sentence, RPE, EMA, MD, FDA, SAS, Choroidal neovascularization, Cell, Human, Patient, Glaucoma, Gene expression

Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.

Key Points: 
  • Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.
  • A substantially de-risked platform and two first-in-class gene therapies heading to the clinic, having the potential to become future blockbusters.
  • PARIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches today with seed finance from Pureos Bioventures and ND Capital.
  • PulseSight is currently raising a Series A financing round to advance its programs into clinical proof-of-concept.

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Therapy, IPF, SAN, Week, Research, Integrin, PSC, Investment, DMD, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, Duchenne muscular dystrophy, ELF, Cirrhosis, Tumor microenvironment, Patient, Novartis, TGF, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.
  • Positive safety and efficacy data from 320 mg dose cohort of INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC).
  • At a once-daily dose of 320 mg, bexotegrast was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events.
  • The increase was due to higher operating expenses coupled with a decrease in collaboration revenues under the Novartis collaboration during the quarter.

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, February 21, 2024
Cancer, AstraZeneca, EVP, Drug development, Bristol Myers Squibb, RAS, University, RAF, Therapy, Patient, Oncology, Novartis, Paris Diderot University, Physician, Nursing

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer. Her addition comes at a pivotal time with the Company’s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena’s commitment to driving innovation in the targeted oncology space.

Key Points: 
  • Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
    Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595
    BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.
  • Prior to Ikena, Dr. Germa served as the EVP, Global Medicine Development, and Chief Medical Officer at Transcenta Therapeutics, where she played a pivotal role in shaping strategic goals for the company’s oncology and non-oncology portfolio, ensuring successful execution across all clinical development functions.
  • Dr. Germa added, “I am thrilled to be joining Ikena at a time when it is primed for clinical inflection across the pipeline.
  • Dr. Santillana’s leadership was integral to bringing our programs into the clinic, and we wish him well in his future endeavors.”

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis

Retrieved on: 
Tuesday, February 20, 2024
Health Canada, Denosumab, RANK, Biosimilar, Safety, FRCPC, Novartis, Patient, Osteoporosis, Generic drug

Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.

Key Points: 
  • Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.
  • Health Canada approval based on robust Phase I and Phase III clinical studies.
  • BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, reference medicine: Prolia*).
  • Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass.

FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Infection, GSK, Growth, Molecular biology, Doctor of Pharmacy, Interim, University, Therapy, Pharmacist, Jan Vansina, Patient, Global Oncology, Novartis, NCE, Management

FORE Biotherapeutics today announced the appointment of William R. Hinshaw as the Chief Executive Officer and Director of the Board.

Key Points: 
  • FORE Biotherapeutics today announced the appointment of William R. Hinshaw as the Chief Executive Officer and Director of the Board.
  • Prior to joining Fore, he was the President, CEO and Board member of Axcella Therapeutics, a clinical-stage and publicly traded biopharmaceutical company developing novel therapies for complex diseases.
  • He also played a key role on the Global Oncology Executive Committee, including leading crucial strategic programs to maximize the portfolio and develop the pipeline.
  • Fore is poised to develop targeted treatments that can have a transformational impact on the lives of patients suffering from cancer,” said Mr. Hinshaw.

Wael Fayad and Stephen Hallenbeck Appointed Partners at Hildred Capital Management

Retrieved on: 
Monday, February 26, 2024
Professional Services, Health, Insurance, Other Health, Finance, Consulting, Banking, Schering-Plough, Deutsche Bank, Marketing, Entrepreneurship, Growth, Business development, Risk, Novartis, Corporation, Partner

Hildred Capital Management (“Hildred”), a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies, today announced that Wael Fayad and Stephen Hallenbeck have both been appointed Partners at the firm.

Key Points: 
  • Hildred Capital Management (“Hildred”), a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies, today announced that Wael Fayad and Stephen Hallenbeck have both been appointed Partners at the firm.
  • On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon stated:
    "We are pleased to announce the promotions of Wael and Stephen, which reflect the vital impact and contributions that each of them has had on the growth of our firm.
  • Wael is an integral part of our team and has been intimately involved in strategically managing several of our portfolio companies, including Carlin Consumer Health, Hyland’s Naturals, and Crown Laboratories.
  • He then worked at Forest Laboratories Inc. for 14 years and served as Corporate Vice President of Business Development.

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Retrieved on: 
Wednesday, February 21, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Therapy, Pfizer, Gilead Sciences, Multimedia, B.A, University, Sofinnova, Annual general meeting, PLC, Chairperson, Élan, Hyperion, Patient, Novartis, Intercept Pharmaceuticals, Horizon Therapeutics, Chair, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240221419945/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240221419945/en/
    Upon election by the shareholders at Prothena’s Annual General Meeting later this year, the Board intends to appoint Mr. Welch as Chair of the Board.
  • Dr. Ekman will step down as Chair and continue to serve on the board as Chair Emeritus, following the anticipated appointment of Mr. Welch.
  • The entire Prothena Board expresses their sincere gratitude for Dr. Ekman’s valuable service as Chair.
  • Dr. Harfstrand has been a director since 2015 and the entire Prothena Board acknowledges and appreciates his positive impact during his service.

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, General Health, Pharmaceutical, Health, Toxicity, Growth, Ovarian cancer, Radiopharmaceutical, Patient, Anal cancer, Bicycle, McKinsey & Company, Head, Cervical cancer, EV, Neoplasm, ATM, Therapy, Food and Drug Administration, TNBC, Net, Former, CMC, Thromboxane A2, Immune system, NSCLC, MUC, Peripheral neuropathy, SunOpta, Safety, Ovary, Participation, Knowledge, Novartis, Lazard, BRC, FDA, Cancer, Food, Pembrolizumab, Government, ADC, Brentuximab vedotin, CD137, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.
  • We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.
  • Validating the company’s Bicycle® Radio Conjugates (BRC™) pipeline and partner for success, with updates expected from its wholly owned BRC program by mid-2024.
  • Advancing the company’s Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) immune-oncology pipeline through innovative partnerships.

Iron Restriction Keeps Blood Stem Cells Young

Retrieved on: 
Friday, March 8, 2024
Bone marrow, Multimedia, Iron, Blood, Inflammation, Albert Einstein, Novartis, HSC, Ageing, Animal, Cell, Risk, B cell, University, Cell biology, Cell Stem Cell, Medicine, DRS, Research, Mouse

BRONX, N.Y., March 8, 2024 /PRNewswire/ -- As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.

Key Points: 
  • BRONX, N.Y., March 8, 2024 /PRNewswire/ -- As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.
  • "So basically, iron restriction governs and protects the regenerative capacity of stem cells—their ability to divide and to differentiate into blood cells," said the paper's co-corresponding author Yun-Ruei Kao, Ph.D. , research assistant professor of oncology and of medicine at Einstein.
  • Compared with controls, aged HSCs exposed to iron chelation produced significantly more blood cells after their HSCs were transplanted into other mice.
  • Dr. Will is currently exploring HSCs and iron from several angles: how to safely limit iron in HSCs during aging; whether restricting iron levels within HSCs can prevent their aging-associated transformation into cancerous HSCs; and to what extent other adult stem cells, such as those in the gut, depend on iron restriction to reliably regenerate tissues and organs.

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
Tuesday, February 27, 2024
Rubius, Odyssey, Senior, Inborn errors of metabolism, Investment, Drug development, Growth, Sale, IPO, University, Intuitive Surgical, Neurodegenerative disease, Analog Devices, National academy, J. P. Morgan, MIT, Genetic distance, American Philosophical Society, Business development, Journal, Therapy, Imatinib, SRL Diagnostics, MidOcean Partners, Distinction, Laboratory, Cornell University, Drug discovery, Weill Cornell Medicine, Provost, Panasonic Executive Partner, Abbott Laboratories, Flagship, Novartis, Medtronic, MACP, Harvard Medical School, Nilotinib, American Academy, Yale School of Medicine, JPMorgan Chase, AI, MD, Flagship Pioneering, Harvard University, MassMutual, Executive, Cancer, Management

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.